Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Journey Medical reports Q2 loss, stock rises after slightly exceeded revenues and success of Amrozi

Journey Medical recorded a Q2 2025 EPS loss of $0.16 and a net loss of $3.8 million, but slightly beat revenue expectations with $15.01 million. The stock rose 8.51% in after-hours trading to $8.00, supported by strong prescription volumes for the new rosacea drug Amrozi and the company’s target of achieving positive EBITDA by the end of 2025. Management emphasised expanding market reach and a reimbursement strategy, while competition from generics and reimbursement risks remain. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2015, Journey Energy has already paid €0.22 in dividends. The last payout was in October 2015.

Financials

In the last quarter, Journey Energy had revenue of €31.35m and net profit of €11.41m

(EUR)	June 2026	YoY
Revenue	31.35m	7.55%
Gross profit	17.48m	2.39%
Net profit	11.41m	350.33%
EBITDA	17.86m	56.72%

Fundamentals

Metric	Value
Market capitalization	€194.24m
Number of shares	67.48m
52-week high/low	€4.33 - €1.93
Dividends	No
Beta	1.57
P/E ratio	11.94
PEG ratio	0.23
P/B ratio	0.86
P/S ratio	1.72

Company profile

Journey Energy Inc. engages in the exploration, development, and production of crude oil and natural gas in the province of Alberta, Canada. The company was formerly known as Sword Energy Inc. and changed its name to Journey Energy Inc. in July 2012. Journey Energy Inc. was founded in 2007 and is headquartered in Calgary, Canada.